Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2021

Open Access 01-12-2021 | Affective Disorder | Research article

The association between keloid and osteoporosis: real-world evidence

Authors: Chun-Ching Lu, Hao Qin, Zi-Hao Zhang, Cong-Liang Zhang, Ying-Yi Lu, Chieh-Hsin Wu

Published in: BMC Musculoskeletal Disorders | Issue 1/2021

Login to get access

Abstract

Background

Keloids are characterized by disturbance of fibroblast proliferation and apoptosis, deposition of collagen, and upregulation of dermal inflammation cells. This benign dermal fibro-proliferative scarring condition is a recognized skin inflammation disorder. Chronic inflammation is a well-known contributor to bone loss and its sequelae, osteoporosis. They both shared a similar pathogenesis through chronic inflammation. We assessed whether keloids increase osteoporosis risk through using National Health Insurance Research Database.

Methods

The 42,985 enrolled patients included 8597 patients with keloids but no history of osteoporosis; 34,388 controls without keloids were identified from the general population and matched at a one-to-four ratio by age, gender. Kaplan-Meier method was applied to determine cumulative incidence of osteoporosis. Cox proportional hazard regression analysis was performed after adjustment of covariates to estimate the effect of keloids on osteoporosis risk.

Results

Of the 8597 patients with keloids, 178 (2.07%) patients were diagnosed with osteoporosis while in the 34,388 controls, 587 (1.71%) were diagnosed with osteoporosis. That is, the keloids patients had 2.64-fold higher risk of osteoporosis compared to controls after adjustment for age, gender, Charlson Comorbidity Index and related comorbidities. The association between keloids and osteoporosis was strongest in patients younger than 50 years (hazard ratio = 7.06%) and in patients without comorbidities (hazard ratio = 4.98%). In the keloids patients, a high incidence of osteoporosis was also associated with advanced age, high Charlson Comorbidity Index score, hyperlipidemia, chronic liver disease, stroke, and depression.

Conclusions

Osteoporosis risk was higher in patients with keloids compared to controls, especially in young subjects and subjects without comorbidities.
Literature
1.
2.
3.
Wolfram D, Tzankov A, Pulzl P, Piza-Katzer H. Hypertrophic scars and keloids--a review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg. 2009;35:171–81.PubMedCrossRef
4.
Halim AS, Emami A, Salahshourifar I, Kannan TP. Keloid scarring: understanding the genetic basis, advances, and prospects. Arch Plast Surg. 2012;39:184–9.PubMedPubMedCentralCrossRef
5.
Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med. 2011;17:113–25.PubMedCrossRef
6.
Chen Y, Gao JH, Yan X, Song M, Liu XJ. Location of predisposing gene for one Han Chinese keloid pedigree. Zhonghua Zheng Xing Wai Ke Za Zhi. 2007;23:137–40.PubMed
7.
Pavone V, Testa G, Giardina SMC, Vescio A, Restivo DA, et al. Pharmacological therapy of osteoporosis: a systematic current review of literature. Front Pharmacol. 2017;8:803.PubMedPubMedCentralCrossRef
8.
Zhao W, Shen G, Ren H, Liang D, Yu X, et al. Therapeutic potential of microRNAs in osteoporosis function by regulating the biology of cells related to bone homeostasis. J Cell Physiol. 2018;233:9191–208.PubMedCrossRef
9.
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-95.
10.
Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–33.PubMedCrossRef
11.
Ray NF, Chan JK, Thamer M, Melton LJ 3rd. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24–35.PubMedCrossRef
12.
Lyles CR, Schafer AL, Seligman HK. Income, food insecurity, and osteoporosis among older adults in the 2007-2008 National Health and nutrition examination survey (NHANES). J Health Care Poor Underserved. 2014;25:1530–41.PubMedCrossRef
13.
Xie Z, He Y, Sun Y, Lin Z, Yang M, et al. Association between pulmonary fibrosis and osteoporosis in the elderly people: a case-control study. Medicine (Baltimore). 2016;95:e5239.CrossRef
14.
Bagabir R, Byers RJ, Chaudhry IH, Muller W, Paus R, et al. Site-specific immunophenotyping of keloid disease demonstrates immune upregulation and the presence of lymphoid aggregates. Br J Dermatol. 2012;167:1053–66.PubMedCrossRef
15.
La Montagna G, Vatti M, Valentini G, Tirri G. Osteopenia in systemic sclerosis. Evidence of a participating role of earlier menopause. Clin Rheumatol. 1991;10:18–22.PubMedCrossRef
16.
Di Munno O, Mazzantini M, Massei P, Ferdeghini M, Pitaro N, et al. Reduced bone mass and normal calcium metabolism in systemic sclerosis with and without calcinosis. Clin Rheumatol. 1995;14:407–12.PubMedCrossRef
17.
Wu CY, Lu YY, Lu CC, Su YF, Tsai TH, et al. Osteoporosis in adult patients with atopic dermatitis: A nationwide population-based study. PLoS One. 2017;12:e0171667.PubMedPubMedCentralCrossRef
18.
Lu YY, Lu CC, Yu WW, Zhang L, Wang QR, et al. Keloid risk in patients with atopic dermatitis: a nationwide retrospective cohort study in Taiwan. BMJ Open. 2018;8:e022865.PubMedPubMedCentralCrossRef
19.
Sun LM, Wang KH, Lee YC. Keloid incidence in Asian people and its comorbidity with other fibrosis-related diseases: a nationwide population-based study. Arch Dermatol Res. 2014;306:803–8.PubMedCrossRef
20.
Humbert PG, Dupond JL, Rochefort A, Vasselet R, Lucas A, et al. Localized scleroderma--response to 1,25-dihydroxyvitamin D3. Clin Exp Dermatol. 1990;15:396–8.PubMedCrossRef
21.
22.
Lee DE, Trowbridge RM, Ayoub NT, Agrawal DK. High-mobility group box Protein-1, matrix Metalloproteinases, and vitamin D in keloids and hypertrophic scars. Plast Reconstr Surg Glob Open. 2015;3:e425.PubMedPubMedCentralCrossRef
23.
Zhang GY, Cheng T, Luan Q, Liao T, Nie CL, et al. Vitamin D: a novel therapeutic approach for keloid, an in vitro analysis. Br J Dermatol. 2011;164:729–37.PubMedCrossRef
24.
Yu D, Shang Y, Luo S, Hao L. The TaqI gene polymorphisms of VDR and the circulating 1,25-dihydroxyvitamin D levels confer the risk for the keloid scarring in Chinese cohorts. Cell Physiol Biochem. 2013;32:39–45.PubMedCrossRef
25.
Gong ZH, Ji JF, Yang J, Xiang T, Zhou CK, et al. Association of plasminogen activator inhibitor-1 and vitamin D receptor expression with the risk of keloid disease in a Chinese population. Kaohsiung J Med Sci. 2017;33:24–9.PubMedCrossRef
26.
Seeman E, Delmas PD. Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354:2250–61.PubMedCrossRef
27.
Graat-Verboom L, Smeenk FW, van den Borne BE, Spruit MA, Jansen FH, et al. Progression of osteoporosis in patients with COPD: a 3-year follow up study. Respir Med. 2012;106:861–70.PubMedCrossRef
28.
Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257:88–91.PubMedCrossRef
29.
Arima J, Huang C, Rosner B, Akaishi S, Ogawa R. Hypertension: a systemic key to understanding local keloid severity. Wound Repair Regen. 2015;23:213–21.PubMedCrossRef
30.
31.
Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci. 2017;18.
32.
Shi C, Zhu J, Yang D. The pivotal role of inflammation in scar/keloid formation after acne. Dermatoendocrinol. 2017;9:e1448327.PubMedCrossRef
33.
Postlethwaite AE, Smith GN, Mainardi CL, Seyer JM, Kang AH. Lymphocyte modulation of fibroblast function in vitro: stimulation and inhibition of collagen production by different effector molecules. J Immunol. 1984;132:2470–7.PubMedCrossRef
34.
Chen W, Fu X, Sun X, Sun T, Zhao Z, et al. Analysis of differentially expressed genes in keloids and normal skin with cDNA microarray. J Surg Res. 2003;113:208–16.PubMedCrossRef
35.
36.
Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov. 2012;11:234–50.PubMedCrossRef
37.
De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R, et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 2006;54:3551–63.PubMedCrossRef
38.
39.
Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33:1290–7.PubMedPubMedCentralCrossRef
40.
Liu Y, Yang D, Xiao Z, Zhang M. miRNA expression profiles in keloid tissue and corresponding normal skin tissue. Aesthet Plast Surg. 2012;36:193–201.CrossRef
41.
Kashiyama K, Mitsutake N, Matsuse M, Ogi T, Saenko VA, et al. miR-196a downregulation increases the expression of type I and III collagens in keloid fibroblasts. J Invest Dermatol. 2012;132:1597–604.PubMedCrossRef
42.
Li C, Bai Y, Liu H, Zuo X, Yao H, et al. Comparative study of microRNA profiling in keloid fibroblast and annotation of differential expressed microRNAs. Acta Biochim Biophys Sin (Shanghai). 2013;45:692–9.CrossRef
43.
44.
Wu ZY, Lu L, Liang J, Guo XR, Zhang PH, et al. Keloid microRNA expression analysis and the influence of miR-199a-5p on the proliferation of keloid fibroblasts. Genet Mol Res. 2014;13:2727–38.PubMedCrossRef
45.
De-Ugarte L, Yoskovitz G, Balcells S, Guerri-Fernandez R, Martinez-Diaz S, et al. MiRNA profiling of whole trabecular bone: identification of osteoporosis-related changes in MiRNAs in human hip bones. BMC Med Genet. 2015;8:75.
46.
Rossi M, Pitari MR, Amodio N, Di Martino MT, Conforti F, et al. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol. 2013;228:1506–15.PubMedCrossRef
47.
Wang T, Feng Y, Sun H, Zhang L, Hao L, et al. miR-21 regulates skin wound healing by targeting multiple aspects of the healing process. Am J Pathol. 2012;181:1911–20.PubMedCrossRef
48.
Cottonham CL, Kaneko S, Xu L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem. 2010;285:35293–302.PubMedPubMedCentralCrossRef
49.
Liu Y, Wang X, Yang D, Xiao Z, Chen X. MicroRNA-21 affects proliferation and apoptosis by regulating expression of PTEN in human keloid fibroblasts. Plast Reconstr Surg. 2014;134:561e–73e.PubMedCrossRef
50.
51.
Liu Y, Li Y, Li N, Teng W, Wang M, et al. TGF-beta1 promotes scar fibroblasts proliferation and transdifferentiation via up-regulating MicroRNA-21. Sci Rep. 2016;6:32231.PubMedPubMedCentralCrossRef
52.
53.
Garcia Palacios V, Robinson LJ, Borysenko CW, Lehmann T, Kalla SE, et al. Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 Cells by estrogen and phytoestrogens. J Biol Chem. 2005;280:13720–7.PubMedCrossRef
54.
Robbins J, Hirsch C, Whitmer R, Cauley J, Harris T. The association of bone mineral density and depression in an older population. J Am Geriatr Soc. 2001;49:732–6.PubMedCrossRef
55.
Wong SY, Lau EM, Lynn H, Leung PC, Woo J, et al. Depression and bone mineral density: is there a relationship in elderly Asian men? Results from Mr. Os (Hong Kong). Osteoporos Int. 2005;16:610–5.PubMedCrossRef
56.
Huang WS, Hsu JW, Huang KL, Bai YM, Su TP, et al. Post-traumatic stress disorder and risk of osteoporosis: a nationwide longitudinal study. Stress Health. 2018;34:440–5.PubMedCrossRef
57.
Furtado F, Hochman B, Farber PL, Muller MC, Hayashi LF, et al. Psychological stress as a risk factor for postoperative keloid recurrence. J Psychosom Res. 2012;72:282–7.PubMedCrossRef
Metadata
Title
The association between keloid and osteoporosis: real-world evidence
Authors
Chun-Ching Lu
Hao Qin
Zi-Hao Zhang
Cong-Liang Zhang
Ying-Yi Lu
Chieh-Hsin Wu
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2021
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-020-03898-8

Other articles of this Issue 1/2021

BMC Musculoskeletal Disorders 1/2021 Go to the issue

Research article

Is coracoclavicular reconstruction necessary in hook plate fixation for acute unstable acromioclavicular dislocation?

Correction

Correction to: Treatment strategy for atypical ulnar fracture due to severely suppressed bone turnover caused by long-term bisphosphonate therapy: a case report and literature review

Study protocol

The influence of a cognitive behavioural approach on changing patient expectations for conservative care in shoulder pain treatment: a protocol for a pragmatic randomized controlled trial

Research

Incisional paresthesia following clavicle plate fixation: does it matter to patients?

Research article

Prevalence and characteristics of the aberrant anterior tibial artery: a single-center magnetic resonance imaging study and scoping review

Research

Effect of nutritional status before femoral neck fracture surgery on postoperative outcomes: a retrospective study